A Pilot Randomized Clinical Trial of a Peer Support Intervention for Hematopoietic Stem Cell Transplantation

Peer support has been associated with improved patient-reported outcomes (PROs), including reduced psychological distress, among patients undergoing hematopoietic stem cell transplantation. Structured interventions tailored for this population are limited. This study assessed the feasibility, acceptability, and preliminary effects of a scalable peer support intervention for reducing psychological distress and enhancing quality of life (QOL) post-HSCT. We conducted a pilot randomized clinical trial evaluating the Supporting Transplant Experiences with Peer Program (STEPP), a five-session, telephone-based intervention delivered by an HSCT survivor offering psychoeducation and coping strategies. Participants were recruited 1-2 weeks pre-HSCT admission and randomized to STEPP or usual care. Feasibility was defined as ≥60% enrollment and ≥60% completing ≥3 sessions. Acceptability was assessed using the Client Satisfaction Questionnaire (CSQ; ≥3/4 mean benchmark). PRO measures of anxiety, depression (HADS), post-traumatic stress (PCL-C), QOL (FACT-BMT), social support (SSEQ), and self-efficacy (CASE) were assessed pre-HSCT and at 30 and 60 days post-HSCT. Mixed-effects models explored STEPP's preliminary effects. We enrolled 77% (90/117) of eligible patients (STEPP n=45; usual care n=45). Twelve became ineligible due to HSCT cancellation or postponement. Among 78 active participants (mean age 58.9 years (SD=12.3); 57.7% women), all STEPP participants completed ≥3 sessions, and the mean CSQ score was 3.5. STEPP showed small-to-moderate improvements in Day 30 anxiety (d=-0.36) and Day 60 anxiety (d=-0.58), depression (d=-0.25), post-traumatic stress (d=-0.28), QOL (d=0.48), social support (d=0.36), and self-efficacy (d=0.46). STEPP exceeds feasibility and acceptability thresholds, showing promising psychosocial benefits warranting a fully powered multi-site efficacy trial. This study was preregistered on ClinicalTrials.gov (NCT06010017).

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2026-04-07
DOI
https://doi.org/10.1182/bloodadvances.2025018918
Primary Topic
Cancer survivorship and care
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Pilot Randomized Clinical Trial of a Peer Support Intervention for Hematopoietic Stem Cell Transplantation

Corey S. Cutler, Jeff C. Huffman, Hermioni L. Amonoo, Michelle Guo et al.
Blood Advances
Cancer survivorship and care
article

A Pilot Randomized Clinical Trial of a Peer Support Intervention for Hematopoietic Stem Cell Transplantation

Corey S. Cutler, Jeff C. Huffman, Hermioni L. Amonoo, Michelle Guo, Michael Mate-Kole, Annabella C. Boardman, Emma D. Wolfe, Emma P Keane, Isabella S. Larizza, Heather S. Jim, Joseph A. Greer, Brian C. Healy, Areej El-Jawahri, Stephanie J. Lee, Lisa M Gudenkauf
article en

Abstract

Peer support has been associated with improved patient-reported outcomes (PROs), including reduced psychological distress, among patients undergoing hematopoietic stem cell transplantation. Structured interventions tailored for this population are limited. This study assessed the feasibility, acceptability, and preliminary effects of a scalable peer support intervention for reducing psychological distress and enhancing quality of life (QOL) post-HSCT. We conducted a pilot randomized clinical trial evaluating the Supporting Transplant Experiences with Peer Program (STEPP), a five-session, telephone-based intervention delivered by an HSCT survivor offering psychoeducation and coping strategies. Participants were recruited 1-2 weeks pre-HSCT admission and randomized to STEPP or usual care. Feasibility was defined as ≥60% enrollment and ≥60% completing ≥3 sessions. Acceptability was assessed using the Client Satisfaction Questionnaire (CSQ; ≥3/4 mean benchmark). PRO measures of anxiety, depression (HADS), post-traumatic stress (PCL-C), QOL (FACT-BMT), social support (SSEQ), and self-efficacy (CASE) were assessed pre-HSCT and at 30 and 60 days post-HSCT. Mixed-effects models explored STEPP's preliminary effects. We enrolled 77% (90/117) of eligible patients (STEPP n=45; usual care n=45). Twelve became ineligible due to HSCT cancellation or postponement. Among 78 active participants (mean age 58.9 years (SD=12.3); 57.7% women), all STEPP participants completed ≥3 sessions, and the mean CSQ score was 3.5. STEPP showed small-to-moderate improvements in Day 30 anxiety (d=-0.36) and Day 60 anxiety (d=-0.58), depression (d=-0.25), post-traumatic stress (d=-0.28), QOL (d=0.48), social support (d=0.36), and self-efficacy (d=0.46). STEPP exceeds feasibility and acceptability thresholds, showing promising psychosocial benefits warranting a fully powered multi-site efficacy trial. This study was preregistered on ClinicalTrials.gov (NCT06010017).

Blood Advances
Brigham and Women's Hospital (US), Boston Medical Center (US), Moffitt Cancer Center (US), Massachusetts General Hospital (US), Fred Hutch Cancer Center (US), Dana-Farber Cancer Institute (US), Mass General Brigham (US)
Openalex Percentile: Top 31%
Cancer survivorship and care
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.